Phase 1 × Carcinoma, Transitional Cell × Thoracic × Clear all
NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Active not recruiting
94 enrolled
NCT06451497 2026-04-02

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

Phase 1 Recruiting
100 enrolled
NCT04514484 2026-03-23

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

Phase 1 Active not recruiting
8 enrolled
NCT06781983 2026-01-07

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Innate Pharma

Phase 1 Recruiting
145 enrolled
NCT04272034 2025-10-16

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Incyte Corporation

Phase 1 Terminated
105 enrolled
NCT05107674 2025-09-09

A Study of NX-1607 in Adults With Advanced Malignancies

Nurix Therapeutics, Inc.

Phase 1 Recruiting
345 enrolled
NCT04458259 2025-08-28

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Pfizer

Phase 1 Terminated
88 enrolled
NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Exelixis

Phase 1 Active not recruiting
914 enrolled
NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

Phase 1 Recruiting
30 enrolled
NCT05958199 2025-06-27

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

NextPoint Therapeutics, Inc.

Phase 1 Suspended
131 enrolled
NCT03212404 2025-02-03

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Checkpoint Therapeutics, Inc.

Phase 1 Active not recruiting
272 enrolled 3 FDA
NCT04660929 2024-12-18

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Carisma Therapeutics Inc

Phase 1 Active not recruiting
48 enrolled
NCT02635672 2024-11-15

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Vincerx Pharma, Inc.

Phase 1 Completed
110 enrolled
NCT06034860 2024-11-01

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Molecular Templates, Inc.

Phase 1 Terminated
15 enrolled
NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled
NCT05069935 2023-09-21

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
16 enrolled
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled